Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure

Documenti analoghi

• Prediction of new‐onset heart failure in patients with type 2 diabetes derived from ALTITUDE and CANVAS
  di: Fatema Said, et al.
  Pubblicazione: (2024)
• Semaglutide and cardiovascular risk in type 1 diabetes: A predictive modelling analysis in a double‐blind, randomised, placebo‐controlled cross‐over trial
  di: Luxcia Kugathasan, et al.
  Pubblicazione: (2026)
• Metabolic shifts in plasma amino acids and related metabolites in response to SGLT2 inhibition and hyperglycemia in type 1 diabetes
  di: Luxcia Kugathasan, et al.
  Pubblicazione: (2025)
• Effects of ertugliflozin on uric acid and gout‐related outcomes in persons with type 2 diabetes and cardiovascular disease: Post hoc analyses from VERTIS CV
  di: Vikas S. Sridhar, et al.
  Pubblicazione: (2024)
• Association of Tirzepatide With Kidney Parameters in Participants With Obesity and Prediabetes From SURMOUNT ‐1 Over 176 Weeks
  di: Hiddo J. L. Heerspink, et al.
  Pubblicazione: (2026)